Get the Stockscreener App
1.02
0.99%
0.01
After Hours:
1.04
0.02
+1.96%
Codexis Inc stock is traded at $1.02, with a volume of 2.62M.
It is up +0.99% in the last 24 hours and down -29.17% over the past month.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
See More
Previous Close:
$1.01
Open:
$1.02
24h Volume:
2.62M
Relative Volume:
2.37
Market Cap:
$92.13M
Revenue:
$70.14M
Net Income/Loss:
$-76.24M
P/E Ratio:
-0.9189
EPS:
-1.11
Net Cash Flow:
$-57.06M
1W Performance:
-4.67%
1M Performance:
-29.17%
6M Performance:
-59.36%
1Y Performance:
-66.45%
1-Day Range:
$0.97
$1.085
1-Week Range:
$0.97
$1.24
52-Week Range:
$0.97
$3.87
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
1.02 | 91.23M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
CDXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
[Form 4] CODEXIS, INC. Insider Trading Activity - Stock Titan
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11 - GlobeNewswire
5,280-share RSU vesting sale at CDXS (NASDAQ: CDXS) - Stock Titan
Codexis Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Codexis (CDXS) Projected to Post Earnings on Thursday - MarketBeat
Is Codexis (NASDAQ:CDXS) Weighed On By Its Debt Load? - 富途牛牛
Codexis to Participate in TD Cowen 46th Annual Health Care Conference - The Manila Times
What makes Codexis Inc. stock attractive to growth fundsMarket Activity Report & Weekly High Return Forecasts - mfd.ru
What’s next for Codexis Inc. stock2025 Historical Comparison & Risk Managed Investment Entry Signals - mfd.ru
Positive Sentiment Still Eludes Codexis, Inc. (NASDAQ:CDXS) Following 29% Share Price Slump - simplywall.st
Macro Review: Does Codexis Inc offer margin of safetyGlobal Markets & Precise Buy Zone Identification - baoquankhu1.vn
Does Codexis Inc. stock trade at a discount to peersWeekly Investment Summary & Free Growth Oriented Trading Recommendations - mfd.ru
Codexis (CDXS) Achieves ISO 9001:2015 Certification - GuruFocus
Codexis Inc. Achieves ISO 9001:2015 Certification for Quality Management Excellence - Quiver Quantitative
What Codexis’ new ISO 9001 status means for enzyme buyers - Stock Titan
Codexis Achieves ISO 9001:2015 Certification - GlobeNewswire
Analysts Expect Breakeven For Codexis, Inc. (NASDAQ:CDXS) Before Long - Yahoo Finance
RSI Check: What makes Codexis Inc stock attractive todayQuarterly Trade Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Enzyme Engineering Market to Get an Explosive Growth | Novozymes - openPR.com
Biofuel Enzymes Market Set to Soar: Innovations Driving - openPR.com
Aberdeen Group plc Expands Stake in Codexis Inc with Significant Share Acquisition - GuruFocus
MACD Signal: Will Codexis Inc benefit from rising consumer demandMarket Performance Recap & Daily Price Action Insights - baoquankhu1.vn
Moving Averages: What are Codexis Incs recent SEC filings showingQuarterly Trade Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Aug PreEarnings: What is DYCQRs book value per shareWeekly Investment Report & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Dividend Watch: Is Codexis Inc. stock vulnerable to regulatory risks2025 Sector Review & Daily Momentum Trading Reports - Bộ Nội Vụ
Codexis and Axolabs Partner to Advance Enzymatic RNA Manufacturing - Contract Pharma
How Codexis Inc. stock reacts to Fed rate cutsShare Buyback & Smart Swing Trading Alerts - ulpravda.ru
Codexis CSO Stefan Lutz sells $7949 in shares By Investing.com - Investing.com Nigeria
Codexis CSO Stefan Lutz sells $7949 in shares - Investing.com
Is Codexis Inc. stock safe for conservative investorsJuly 2025 Short Interest & Safe Entry Momentum Tips - Улправда
Codexis (CDXS) Partners with Axolabs for Innovative RNA Manufact - GuruFocus
New partnership tests greener way to mass-produce RNA medicines - Stock Titan
Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics - Yahoo Finance
Q3 2025 Codexis Inc Earnings Call Transcript - GuruFocus
Enzyme Engineering Market Set for Rapid Growth and Trend - openPR.com
Codexis strengthens board with biotech veteran Arthur Levin - MSN
Will Codexis Inc. stock benefit from green energy trendsJuly 2025 Levels & Free Weekly Watchlist of Top Performers - DonanımHaber
Opaleye Management Inc. Reduces Stake in Codexis Inc. - GuruFocus
How Codexis Inc. stock reacts to job market dataPortfolio Profit Report & Expert-Curated Trade Recommendations - Улправда
Opaleye management sells Codexis (CDXS) shares worth $877,846 By Investing.com - Investing.com Nigeria
Opaleye management sells Codexis (CDXS) shares for $1.87 million By Investing.com - Investing.com South Africa
Opaleye management sells Codexis (CDXS) shares for $1.87 million - Investing.com
Codexis : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com
Opaleye management sells Codexis (CDXS) shares worth $877,846 - Investing.com
MACD Signal: Why Codexis Inc stock could see breakout soonJuly 2025 Trade Ideas & AI Enhanced Trading Alerts - moha.gov.vn
Specialty Enzymes Market size to cross $12.2 Billion by 2035 | - openPR.com
Perhaps timely catching Codexis Inc (CDXS) would be a good idea - Setenews
Is Codexis Inc. stock supported by strong fundamentalsTrade Risk Report & Verified Technical Signals - Newser
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.90%
2.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):